Key result
Stroke prevention efficacy drives ~33% of patient preference when choosing OACs for AF.
Why the study?
Stroke prevention in patients with atrial fibrillation using anticoagulants requires balancing reduced ischemic stroke risk against increased serious bleeding risk.
Cross-Sectional (n=131)
No
May inform anticoagulant selection in AF; leaves open optimal stroke-bleeding trade-offs in real-world cohorts.
Stroke prevention in patients with atrial fibrillation (AF) using anticoagulants involves weighing the benefits of reduced ischemic stroke1,2 against the elevated risks of serious bleeding events.3 Warfarin and direct oral anticoagulants (DOACs) are the available oral anticoagulants for this indication.
No takes yet. Share an insight, caveat, or question.
Pang et al. (2023) conducted a cross-sectional in Atrial fibrillation (n=131). Oral anticoagulant attributes was evaluated on Relative attribute importance. Efficacy in stroke prevention and out-of-pocket cost were the most important attributes for patients when selecting oral anticoagulant medications for atrial fibrillation, accounting for 33% and 22% of relative importance, respectively.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: